Hypolipidemic effects of sea urchin-derived bioactive food additives in monotherapy and in combination with atorvastatin

19 April 2011
Written by Kryizhanovsky S.P., Yatskova M.A., Golovacheva V.D.

  UDK: 616.12‑005.4‑085.272.4:615.324:593.953 | Pages: 29–31 | Read full textDownload PDF 


Examining 45 patients diagnosed with ‘ischemic heart disease: stable angina of effort (functional class II‑III)’and hypercholesterolemia, the authors have investigated the effects of sea ur‑chinderived bioactive food additive ‘Maristim’ on the lipid exchange indices and determined the ca‑pacity of ‘Maristim’ to decrease the level of total cholesterol, low‑density lipoprotein cholesterol and triglycerides, and to increase relative level of high‑density lipoprotein cholesterol in blood during monotherapy and combined with halved efficient dose of atorvastatin. The high additive effects of the combined therapy appear to be a major focus of interest, thus, requiring further investigation.

Links to authors:

S.P. Kryizhanovsk, M.A. Yatskova, V.D. Golovacheva
Medical Association of Far East Brach of Russian Academy of Sciences (95 Kirova St. Vladivostok 690022 Russia)

  1. Ageev F.T. The combination of high index cardiac risk and normal cholesterol levels: innovative approaches to patient of doctor‑patient, Consilium Medicum, 2008. No. 3. P. 3–11.
  2. Aronov D.M., Lupanov V.P. Atherosclerosis and coronary heart
    disease. M.: Triada, 2009. 245 p.
    3. Dankovceva E.N., Zatejwikov D.A. The ways to increase high‑
    density lipoprotein, Serdce. 2006. V. 5, no. 5. P. 239–241.
    4. Diagnosis and correction of the metabolic disorder for the pre‑
    vention and treatment of atherosclerosis: Russian recommenda‑
    tions, Kardiovask. terapija i profilakt. 2007. Prim. 3. P. 1–26.
    5. Zatejwikov D.A., Talyzin P.A. A new approach to lipid‑lowering
    therapy: the dual inhibition, Farmateka. 2006. no. 13. P. 1–10.
    6. Kulev B.D., Ageev F.T. The effect of different approaches statin
    therapy in patients at high risk in terms of vascular endothelial,
    Kardiologija. 2009. No. 5. P. 4–10.
    7. Susekov A.V. Dual inhibition of cholesterol: new perspectives
    in the treatment of patients with atherosclerosis, Kardiologija.
    2006. No. 1. P. 24–27.
    8. Shljahto E.V., Panov A.V., Gordeev M.L. et.al. Combination
    lipid‑lowering therapy fluvastatin and ezetimibe in patients with
    coronary heart disease after coronary artery bypass grafting, Aktualnye voprosy boleznej serdca i sosudov. 2007. No. 4. P. 8–12.
    9. Grundy S.V., Cleman J.I., Bairey C.N. et al., Implication of recent
    clinical trials for the National Cholesterol Education Programm
    Adult Treatment, Panel 3, Guidelines, Circulation. 2004. Vol. 110.
    P. 227–239.
    10. Nissen S.E., Stephen J.N., Sipahi I. et al., Effect of very high‑
    intensity stain therapy on regression of coronary atherosclerosis.
    The ASTEROID trial, JAMA. 2006. Vol. 295. P. 1556–1565.
    11. Nissen S.E., Tuzcu E.M., Schoenhagen P. et al. Effect of intensive
    compared with moderate lipid‑lowering therapy on progression
    of coronary atherosclerosis. A randomized controlled trial, JAMA.
    2004. Vol. 291. P. 1071–1080.
    12. Smitb S., Alln J., Blairs S. et al. AHA/ACC guidelines for Sec‑
    ondary Prevontion for Patients with coronary and other ath‑
    erosclerosis vascular disease: 200 update, Circulation. 2006.
    Vol. 113. P. 23–63.


Founded in 1997  |  Editions in a year: 4, Articles in one issue: 30 |  ISSN of print version: 1609-1175  |  Ind.: 18410 (Agency "Rospechat’")  |  Edition: 1000 c.